The concern of generic challenges has consistently loomed above copyright’s iconic drug, Viagra, sparking questions about the prospects of connected pharmaceutical portfolios. While first periods saw impressive profits, the intellectual property end has created the path for discounted alternatives, potentially lowering profitability and creating